|Mr. Frederic Chereau||Pres, CEO & Director||590.87k||N/A||1967|
|Dr. Mark A. Kay||Co-Founder & Director||74.69k||N/A||1958|
|Dr. Dean A. Falb||Chief Scientific Officer||391.27k||N/A||1967|
|Dr. Leszek Lisowski Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Adi Barzel||Co-Founder||N/A||N/A||N/A|
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
LogicBio Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 6; Compensation: 8.